Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate

Journal of Biotechnology

Volumn 103, Issue 3, 2003, Pages 257-271

  Bouvier, Anne ^a   Chapline, Jaymi ^a   Boerner, Renee ^a   Jeyarajah, Shanthini ^a   Cook, Susan ^a   Acharya, Prathima S ^a   Henderson, Ian ^b   Schrimsher, Jeffrey L ^a   Shepard, Scot R ^a  

^a Diosynth RTP Inc   (United States)

^b DynPort Vaccine Company LLC   (United States)

Author keywords

Biopharmaceutical production; Botulinum neurotoxins; Disulfide formation; Kinetics; Oxidation; Recombinant protein folding

Indexed keywords

CHROMATOGRAPHY; OXIDATION; PH EFFECTS; THERMODYNAMIC STABILITY; YEAST;

PEPTIDE MAPPING;

PROTEINS;

BOTULINUM TOXIN; BOTULISM VACCINE; CYSTAMINE; CYSTEINE; DISULFIDE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOTULISM; CATION EXCHANGE; CHEMICAL REACTION KINETICS; CIRCULAR DICHROISM; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISULFIDE BOND; DRUG MANUFACTURE; DRUG POTENCY; DRUG SCREENING; FACTORIAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PEPTIDE MAPPING; PH; PICHIA PASTORIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PURIFICATION; SEROTYPE; TEMPERATURE; THERMOSTABILITY; VACCINATION; WESTERN BLOTTING;

PICHIA; PICHIA PASTORIS;

EID: 0142059619     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(03)00106-8     Document Type: Article

References (34)

1. Anderson J.H., Lewis G.E. Clinical evaluation of botulinum toxoids. Lewis G.E. Biomedical Aspects of Botulism. 1981;233-246 Academic Press, New York.
2. Anfinsen C.B. Principles that govern the folding of protein chains. Science. 181:1973;223-230.
3. Antharavally B., Tepp W., DasGupta B.R. Status of Cys residues in the covalent structure of botulism neurotoxin types A, B and E. J. Protein Chem. 17:(3):1998;187-196.
4. Bittner M.A., Das Gupta B.R., Holz R.W. Isolated light chains of botulinum neurotoxins inhibit exocytosis. Studies in digitonin-permeabilized chromaffin cells. J. Biol. Chem. 264:(18):1989;10354-10360.
5. Boerner, R., Chapline, J., Ahn J., Bouvier, A., Shepard, S.R., Jeyarajah, J., Henderson, I. 2001. Characterization of Recombinant Heavy Chain Fragments of Botulinum Neurotoxin, Serotype A and B. ISPPP Meeting, November 2001, Orlando, FL.
6. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie. 82:2000;955-966.
7. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immunol. 66:(10):1998;4817-4822.
8. Cabrele C., Fiori S., Pegoraro S., Moroder L. Redox active cyclic bis(cysteinyl)peptides as catalysts for in vitro oxidative protein folding. Chem. Biol. 9:(6):2002;731-740.
9. Chang J., Li L. Pathways of oxidative folding of α-lactalbumin: a model for illustrating the diversity of disulfide folding pathways. Biochemistry. 41:2002;8405-8413.
10. Creighton T.E. Folding pathways determined using disulfide bonds. Creighton T.E. Protein Folding. 1992;301-351 H. Freeman, New York.
11. Creighton T.E. Protein folding coupled to disulphide bond formation. Biol. Chem. 378:(8):1997;731-744.
12. Darby N., Creighton T.E. Probing protein folding and stability using disulfide bonds. Mol. Biotechnol. 7:1997;57-77.
13. DasGupta B.R., Sugiyama H. A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem. Biophys. Res. Commun. 48:1972;108-112.
14. De Bernardez Clark E. Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12:2001;202-207.
15. De Paiva A.M., Poulain B., Lawrence G.W., Stone C.C., Tauc L., Dolly J.O. A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J. Biol. Chem. 268:1993;20838-20844.
16. Frand A.R., Cuozzo J.W., Kaiser C.A. Pathway for protein disulphide bond formation. Trends Cell Biol. 10:2000;203-210.
17. Gough J.D., Williams R.H., Donofrio A.E., Lees W.J. Folding disulfide-containing proteins faster with an aromatic thiol. J. Am. Chem. Soc. 124:2002;3885-3892.
18. Krieglstein K.G., DasGupta B.R., Henschen A.H. Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Protein Chem. 13:(1):1994;49-57.
19. Kumar N., Kella D., Kinsella J.E. A method for the controlled cleavage of disulfide bonds in proteins in the absence of denaturants. J. Biochem. Biophys. Methods. 11:1985;251-263.
20. Laity J.H., Lester C.C., Shimotakahara S., Zimmerman D.E., Montelione G.T., Scheraga H.A. Structural characterization of an analog of the major rate-determining disulfide folding intermediate of bovine pancreatic ribonuclease A. Biochemistry. 36:(42):1997;12683-12699.
21. La Penotiere H.F., Clayton M.A., Middlebrook J.L. Expression of a large, nontoxic fragment of botulism neurotoxin serotype A and its use as an immunogen. Toxicon. 33:(10):1995;1383-1386.
22. Middleberg A.P.J. Preparative protein refolding. Trends Biotechnol. 20:(10):2002;437-443.
23. Oae S. Organic Sulfur Chemistry: Structure and Mechanism. 1991;CRC Press, Boca Raton, FL.
24. Oguma K., Fujinaga Y., Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol. Immunol. 39:1995;161-168.
25. Potter K.J., Zhang W., Smith L.A., Meagher M.M. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotropic yeast Pichia pastoris. Protein Exp. Purif. 19:2000;393-402.
26. Price-Carter M., Salem Hull M., Goldenberg D.P. Role of Individual disulfide bonds in the stability and folding of a ω-conotoxin. Biochemistry. 37:1998;9851-9861.
27. Ruddon R.W., Bedows E. Assisted protein folding. J. Biol. Chem. 272:(6):1997;3125-3128.
28. Seckler R., Jeanicke R. Protein folding and protein refolding. FASEB J. 6:1992;2545-2552.
29. Shepard S.R., Stone C.B., Cook S., Bouvier A., Boyd G.A., Weatherly G.T., Lydiard D.D., Schrimsher J.L. Recovery of intracellular recombinant proteins from the yeast Pichia pastoris by cell permeabilization. J. Biotechnol. 99:(2):2002;149-160.
30. Simpson L.L. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie. 82:2000;943-953.
31. Smith L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon. 36:(11):1998;1539-1548.
32. Thornton J.M. Disulphide bridges in globular proteins. J. Mol. Biol. 151:(2):1981;261-287.
33. Weatherly G.T., Bouvier A., Lydiard D.D., Chapline J., Henderson I., Schrimsher J.L., Shepard S.R. Initial purification of recombinant botulinum neurotoxin fragments for pharmaceutical production using hydrophobic charge induction chromatography. J. Chromatogr. A. 952:2002;99-110.
34. Wedemeyer W.J., Welker E., Narayan M., Scheraga H.A. Disulfide bonds and protein folding. Biochemistry. 39:2000;4207-4216.